Show simple item record

dc.contributor.editorDe Falco, Valentina
dc.date.accessioned2022-02-24T10:34:40Z
dc.date.available2022-02-24T10:34:40Z
dc.date.issued2022
dc.identifierONIX_20220224_9783036528564_33
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/78735
dc.description.abstractTumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called “oncogene addiction”. According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs.
dc.languageEnglish
dc.subject.classificationbic Book Industry Communication::G Reference, information & interdisciplinary subjects::GP Research & information: general
dc.subject.classificationbic Book Industry Communication::P Mathematics & science::PS Biology, life sciences
dc.subject.other3D spheroids
dc.subject.otherphotothermy
dc.subject.othergold nanoparticles
dc.subject.otherdoxorubicin resistance
dc.subject.othercolorectal cancer
dc.subject.othercellular prion protein
dc.subject.otherPrPC
dc.subject.otherPRNP
dc.subject.othercancer
dc.subject.othercancer stem cell
dc.subject.othertargeted cancer therapy
dc.subject.otherbrain metastases
dc.subject.othertreatment
dc.subject.othernon-small cell lung carcinoma
dc.subject.otherEGFR
dc.subject.otherALK
dc.subject.otherimmunotherapy
dc.subject.otherHDAC6
dc.subject.otherbortezomib-resistance
dc.subject.otherHDAC6-selective inhibitor
dc.subject.otherbortezomib
dc.subject.othercarfilzomib
dc.subject.othermultiple myeloma
dc.subject.otherLMP2
dc.subject.othercombination therapy
dc.subject.othercolorectal cancer cells
dc.subject.otherdrug resistance
dc.subject.other5-Fluorouracil
dc.subject.otherthymidylate synthase
dc.subject.otherexome sequencing
dc.subject.otherCD47
dc.subject.otherimmune activation
dc.subject.otherpro-tumoral macrophages
dc.subject.otherbreast cancer
dc.subject.otherpolo-like kinase 1 (PLK1)
dc.subject.otherpyrazole
dc.subject.otherquantitative structure-activity relationship
dc.subject.otherhybridization
dc.subject.otherovarian cancer
dc.subject.othercisplatin
dc.subject.othercisplatin resistance
dc.subject.otherPARPi
dc.subject.otherniraparib
dc.subject.otherTwist
dc.subject.otherlethality
dc.subject.otherAF4
dc.subject.othercell culture
dc.subject.otherFGFR2
dc.subject.otherHOXA9
dc.subject.otherMLL-AF4
dc.subject.othernucleus
dc.subject.othertarget therapy
dc.subject.othert(4
dc.subject.other11) leukemia
dc.subject.otherradiation-resistant
dc.subject.othercell death
dc.subject.otherERK
dc.subject.otherEMT
dc.subject.othercancer stem cells (CSCs)
dc.subject.otherPD98059
dc.subject.otherPARP inhibitors
dc.subject.otherPARP inhibitor resistance
dc.subject.othersignal transduction networks
dc.subject.otherpathways
dc.subject.otherevent-free survival
dc.subject.otherbiomarkers
dc.subject.otherWNT pathway
dc.subject.othertargeted therapy
dc.subject.otherWee1 kinase
dc.subject.othercell cycle
dc.subject.othertumor resistance
dc.subject.otherlenvatinib
dc.subject.othersorafenib-resistant
dc.subject.otherhepatocellular carcinoma
dc.subject.otherFGFR4
dc.subject.otherautophagy
dc.subject.othermicroRNA
dc.titleTargeted Cancer Therapy and Mechanisms of Resistance
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-2856-4
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036528564
oapen.relation.isbn9783036528571
oapen.pages280
oapen.place.publicationBasel


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/